Jessica Geiger, MD
Medical Oncology · Cleveland, OHNPI 1366763021
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,065 of the $33,128 with a category attached, or 87.7%. 11 manufacturers reported payments, led by Regeneron at 27.7% of the total. 2025 is the largest year on record at $13,162, 5.0 times the $2,617 reported in 2019.
Across 36 payments — averaging $920.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$9K
- Astellas Pharma Global Development$6K
- Janssen Scientific Affairs, LLC$5K
- EMD Serono, Inc.$5K
- Coherus Oncology, Inc.$2K
- Exelixis Inc.$2K
- plus $3K from 5 others
Across 275 payments — averaging $8553.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$531K
- Regeneron$458K
- Alkermes, Inc.$412K
- Janssen Research & Development, LLC$389K
- Merck Healthcare Kgaa$170K
- Merck$131K
- plus $262K from 4 others
What the payments were for
- Consulting fees$29,06588%
- Speaking & faculty fees$2,7828%
- Travel & lodging$6612%
- Food & beverage$6212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 11 | $9,162 |
| Astellas Pharma Global Development | 2 | $6,400 |
| Janssen Scientific Affairs, LLC | 3 | $5,370 |
| EMD Serono, Inc. | 1 | $5,225 |
| Coherus Oncology, Inc. | 2 | $2,388 |
| Exelixis Inc. | 1 | $1,980 |
| Merck | 1 | $1,500 |
| F. Hoffmann-la Roche AG | 2 | $552 |
| Taiho Oncology, Inc. | 6 | $242 |
| AstraZeneca | 6 | $165 |
| Tactile Systems Technology Inc | 1 | $144 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,128 in reported general payments places this provider in the 85th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 33 | $768,237 |
| RetevmoSelpercatinib | 12 | $136,272 |
| Levothyroxine Sodium | 48 | $605 |
| Prochlorperazine Maleate | 23 | $396 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $235 |
| Oxycodone Hcl | 16 | $182 |
| Pantoprazole Sodium | 12 | $110 |
| Dexamethasone | 13 | $104 |
| Ondansetron Hcl | 12 | $92 |
| Sodium FluorideFluoride (Sodium) | 12 | $65 |
| Prednisone | 15 | $29 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Cleveland
- Moshe OrnsteinCleveland$249K
- Suneel KamathCleveland$120K
- William TseCleveland$56K
- Amanda NizamCleveland$46K
- Melinda HsuCleveland$41K
- Jack KhouriCleveland$39K
- Thach-Giao TruongCleveland$31K
- David PeereboomCleveland$23K
- George BuddCleveland$22K
- Smitha KrishnamurthiCleveland$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.